Status:
RECRUITING
Identification of New Serum Diagnostic Markers of Hepatocellular Carcinoma
Lead Sponsor:
Stanford University
Conditions:
Liver Cancer
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to identify blood markers that have the ability to diagnose liver cancer with improved accuracy, so that it can be used alone or in conjunction with alpha-feto protein (AF...
Detailed Description
Liver cancer is a deadly cancer that is typically hard to diagnose and treat. The currently used blood marker for the clinical diagnosis of liver cancer is alpha-feto protein (AFP), which misses 40-60...
Eligibility Criteria
Inclusion
- Patients diagnosed with liver cancer based on biopsy or serum AFP level, associated with characteristic hypervascular liver tumors on triphasic spiral CT scan or MRI.
- Patients with non-cancer liver conditions such as cirrhosis, adenoma, cholangioma, or nodular hyperplasia.
- Patients with hepatitis B or hepatitis C viral infections not associated with liver cancer.
Exclusion
- Patients will be excluded if, upon looking through their medical records, information required for data analysis are missing.
Key Trial Info
Start Date :
November 1 2004
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2025
Estimated Enrollment :
600 Patients enrolled
Trial Details
Trial ID
NCT00373347
Start Date
November 1 2004
End Date
December 1 2025
Last Update
May 4 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Stanford University School of Medicine
Stanford, California, United States, 94305